Inventor · disambiguated record
Scott Glaser
Also filed as: GLASER SCOTT · GLASER SCOTT M · GLASER SCOTT MARTIN
21 granted patents·16 pending applications·395 citations·filing 1994–2024
96Inventor score
Files withBIOGEN IDEC INC9NOVARTIS AG9GLASER SCOTT3APPLIED MOLECULAR EVOLUTION2BRISTOL MYERS SQUIBB CO2
Top patents by PatentIndex Score
37 records- 0196US7951918B2Stabilized polypeptide compositionsBIOGEN IDEC INC·Filed 2007·Granted May 31, 2011·96 cites·52 claims
- 0294US7612178B2Anti-IGF-1R antibodies and uses thereofBIOGEN IDEC INC·Filed 2007·Granted Nov 3, 2009·24 cites·16 claims
- 0393US8147829B2Anti-IGR-1R antibodies and uses thereofHARIHARAN KANDASAMY·Filed 2009·Granted Apr 3, 2012·41 cites·22 claims
- 0492US8084026B2Multispecific binding molecules comprising connecting peptidesGLASER SCOTT·Filed 2007·Granted Dec 27, 2011·31 cites·46 claims
- 0588US11634497B2Anti-CCR7 antibody drug conjugatesNOVARTIS AG·Filed 2018·Granted Apr 25, 2023·5 cites·26 claims
- 0688US8603473B2Modified binding molecules comprising connecting peptidesGLASER SCOTT·Filed 2008·Granted Dec 10, 2013·14 cites·50 claims
- 0788US7960142B2Stabilized polypeptide compositionsBIOGEN IDEC INC·Filed 2007·Granted Jun 14, 2011·16 cites·54 claims
- 0887US7422744B2Methods of treating cancer with alphavbeta3-specific antibodiesAPPLIED MOLECULAR EVOLUTION·Filed 2003·Granted Sep 9, 2008·12 cites·34 claims
- 0985US7700097B2Purification and preferential synthesis of binding moleculesBIOGEN IDEC INC·Filed 2004·Granted Apr 20, 2010·30 cites·38 claims
- 1084US8021661B2Cripto binding moleculesBIOGEN IDEC INC·Filed 2007·Granted Sep 20, 2011·5 cites·29 claims
- 1183US11939397B2ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapiesNOVARTIS AG·Filed 2019·Granted Mar 26, 2024·3 cites·18 claims
- 1281US5792456AMutant BR96 antibodies reactive with human carcinomasBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Aug 11, 1998·42 cites·30 claims
- 1379US6590079B2Anti-αvβ3 recombinant human antibodies, nucleic acids encoding sameIXSYS INC·Filed 1997·Granted Jul 8, 2003·28 cites·39 claims
- 1472US8734795B2Light targeting molecules and uses thereofWANG XINZHONG·Filed 2009·Granted May 27, 2014·1 cites·22 claims
- 1571US11878060B2mRNA-mediated immunization methodsNOVARTIS AG·Filed 2017·Granted Jan 23, 2024·1 cites·13 claims
- 1669US12180291B2Anti-CCR7 antibody drug conjugatesNOVARTIS AG·Filed 2023·Granted Dec 31, 2024·0 cites·17 claims
- 1769US2024336701A1Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapiesNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1865US7422745B2Methods of treating cancer with vαβ3-specific antibodiesAPPLIED MOLECULAR EVOLUTION·Filed 2003·Granted Sep 9, 2008·0 cites·95 claims
- 1965US6331431B1Vacuum device and method for isolating periplasmic fraction from cellsIXSYS INC·Filed 1995·Granted Dec 18, 2001·19 cites·23 claims
- 2061US9409950B2Linker peptides and polypeptides comprising sameMILLER BRIAN ROBERT·Filed 2011·Granted Aug 9, 2016·1 cites·27 claims
- 2161US2007071674A1Polynucleotides encoding novel isoforms of IGSF9MCLACHLAN KAREN·Filed 2006·Application pending·0 cites
- 2260US5728821AMutant BR96 antibodies reactive with human carcinomasBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Mar 17, 1998·25 cites·21 claims
- 2358US2004258616A1Compositions and methods for treating cancer using IGSF9 and LIV-1IDEC PHARMA CORP·Filed 2004·Application pending·0 cites
- 2457US8892364B2Stabilized polypeptide compositionsGLASER SCOTT·Filed 2007·Granted Nov 18, 2014·1 cites·22 claims
- 2557US2009155255A1Cd23 binding molecules and methods of use thereofBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 2655US2006204492A1Compositions and methods for producing enhanced antibodiesHUSE WILLIAM D·Filed 2006·Application pending·0 cites
- 2754US2005239700A1Treatment of cancer using antibodies to LRRC15BIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 2853US2007037205A1Methods and apparatus for cell based screeningPALLADINO MICHAEL A JR·Filed 2006·Application pending·0 cites
- 2950US2009130105A1Compositions that bind multiple epitopes of igf-1rBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 3050US2009047737A1Human LY6-Big Molecules and Methods of UseBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 3149US2023053449A1Dc-sign antibody drug conjugatesNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3249US2003152549A1Methods and apparatus for cell based screeningFiled 2002·Application pending·0 cites
- 3349US2021170043A1Dc-sign antibody conjugates comprising sting agonistsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3446US2022340685A1Combination therapy with entpd2 and cd73 antibodiesNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3546US2022348651A1Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapiesNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3645US2012064080A1Human LY6-Big Molecules and Methods of UseCHU PETER·Filed 2011·Application pending·0 cites
- 3742US2012100140A1Stabilized fc polypeptides with reduced effector function and methods of useREYES CHRISTOPHER L·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Scott Glaser files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →